Search Results for "Cvs Minute Clinic Shingles Vaccine"

11:54 EDT 28th October 2016 | BioPortfolio

Matching Channels


Varicella zoster virus (VZV) is one of eight herpes viruses known to infect humans (and other vertebrates). Varicella-zoster virus is known by many names, including: chickenpox virus, varicella viru...

HPV vaccine

Rotavirus Vaccine GSK

Smallpox Vaccine MVA

Poliovirus Vaccine OPV

Matching News

GSK applies for FDA approval for shingles vaccine

GlaxoSmithKlien, the UK’s biggest drugmaker, is seeking approval from the FDA for a shingles (herpes zoster) vaccine. The vaccine would be for those of 50 years and above to prevent the emergence of...

GSK Seeks Approval for its Blockbuster Shingles Vaccine

GlaxoSmithKline  plc (LSE/NYSE: GSK) today announced that it has submitted a Biologics License Application (BLA) for its candidate shingles vaccine, ShingrixTM, to the United States Food and Drug Ad...

New Shingles Vaccine May Have Higher Efficacy in Older Adults – Medscape

MedscapeNew Shingles Vaccine May Have Higher Efficacy in Older AdultsMedscapeA new two-dose herpes zoster vaccine called HZ/su is safe and reduces the risk for shingles and postherpetic neuralgia by n...

GSK’s candidate shingles vaccine shows high efficacy against shingles

GSK has announced the publication of detailed results from a randomized phase III study (ZOE-70) of its investigational shingles vaccine, Shingrix, showing 90% efficacy in adults aged 70 years and old...

Experimental Shingles Vaccine Looks Quite Effective: Study

WEDNESDAY, Sept. 14, 2016 -- An experimental vaccine against shingles may offer lasting protection for most older adults who receive it, a new clinical trial found. Shingles is a painful rash that's t...

New Shingles Vaccine May Have Higher Efficacy in Older Adults

Phase 3 clinical trial data showed the new shingles vaccine HZ/su is safe and greatly reduces the risk for shingles and postherpetic neuralgia in people 70 years and older. Medscape Medical News

GSK Files BLA for Shingles Vaccine to Compete with Merck

GSK announces U.S. regulatory submission of potential $1 billion Shingrix vaccine for prevention of shingles

BRIEF-GSK submits U.S. application for Shingles vaccine

* Announces U.S. regulatory submission of candidate vaccine for prevention of Shingles

Matching PubMed Articles

The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.

Multiple vaccination visits and administrations can be stressful for infants, parents and healthcare providers. Multivalent combination vaccines can deliver the required number of antigens in fewer in...

Herpes Zoster Vaccine in the Long-Term Care Setting: A Clinical and Logistical Conundrum.

Advancing age is associated with an increased risk of herpes zoster (shingles) infection and latent effects such as postherpetic neuralgia. The herpes zoster vaccine is recommended in those 60 years o...

Influenza vaccine effectiveness: Maintained protection throughout the duration of influenza seasons 2010-2011 through 2013-2014.

Factors, such as age, comorbidities, vaccine type, herd immunity, previous influenza exposure, and antigenic shift, may impact the immune response to the influenza vaccine, protection against circulat...

Herpes zoster and the search for an effective vaccine.

Primary infection with Varicella Zoster Virus (VZV), an exclusively human neurotropic alphaherpsesvirus, results in varicella, more commonly known as chickenpox. Like other alphaherpesviruses, VZV est...

VR-28 Nova Fahrenheit by Jimmy Descant.

Recognizing the contribution art has had in the Mayo Clinic environment since the original Mayo Clinic Building was finished in 1914, Mayo Clinic Proceedings features some of the numerous works of art...

Search Whole site using Google

Quick Search
Advertisement Advertisement